Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Beyond Air's subsidiary, Beyond Cancer, presented updated Phase 1 clinical data for its investigational immunotherapy UNO at AACR 2026, reporting prolonged survival in heavily pretreated cancer patients after a single intratumoral injection. The trial included patients with breast cancer, squamous cell carcinoma, and melanoma, many of whom had exha…